GlaxoSmithKline: US FDA Advisory Committee Votes In Support Of Trials Designed To Evaluate Jemperli (Dostarlimab-Gxly) As A Potential Treatment For Mismatch Repair-Deficient/Microsatellite Instability-High Locally Advanced Rectal Cancer
February 10, 2023
February 10, 2023
LONDON, England, Feb. 10 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Feb. 9, 2023:
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 in support of the question posed to the committee regarding whether data from two proposed single-arm trials will be "sufficient to characterize the benefits and risks" of Jemperli (dostarlimab-gxly) in the cur . . .
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 in support of the question posed to the committee regarding whether data from two proposed single-arm trials will be "sufficient to characterize the benefits and risks" of Jemperli (dostarlimab-gxly) in the cur . . .